FDA finds deficiencies in Mylan's generic Advair; shares fall

(Reuters) – Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline’s blockbuster inhaled lung drug Advair for the second time, as they found “minor deficiencies” in the treatment.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *